Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | LTC4S | Q16873 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240058 | 0.89 | LTC4S (0.47) | LTC4S | |
| SCHEMBL1721647 | 0.81 | LTC4S (0.54) | LTC4S | |
| SCHEMBL1724154 | 0.79 | LTC4S (0.49) | LTC4SMAPTPOLBSMN1; SMN2MEN1 | |
| SCHEMBL559181 | 0.74 | MAPT (0.47) | MAPTPOLBMEN1LMNAKMT2A | |
| SCHEMBL1721650 | 0.73 | LTC4S (0.39) | LTC4SMAPTPOLBSMN1; SMN2MEN1 | |
| SCHEMBL236206 | 0.72 | LTC4S (0.69) | LTC4S | |
| SCHEMBL236327 | 0.71 | LTC4S (0.51) | LTC4S | |
| SCHEMBL1721644 | 0.71 | MDM2 (0.42) | MAPTMEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL27832535 | 0.71 | LTC4S (0.41) | CCR5LTC4SKCNH2 | |
| SCHEMBL2892434 | 0.70 | CES1 (0.50) | MAPTSMN1; SMN2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406223-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103297-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | CCR5 1337/4885ACHE 2105/4885LTC4S 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.